In early 2021, the FDA approved the first long-acting injectable antiretroviral, cabotegravir/rilpivirine (LA-CAB/RPV), for people with HIV who are doing well on their current treatment. A high body mass index (BMI)—30 kg/m² or more—is known to increase the risk of treatment failure, but there's not much data to confirm this because the studies have been small. A recent study aimed to explore this connection in the real world.
The research focused on understanding if a higher BMI impacts the effectiveness of LA-CAB/RPV. They studied how the drug worked in people with different BMIs to find out if it was as effective for those with a higher BMI. The study was designed to look at real-life outcomes, which is different from controlled lab settings.
One key finding was that the drug's effectiveness could be influenced by BMI. This means that people with a higher BMI might not get the same benefits from LA-CAB/RPV as those with a lower BMI. This highlights the importance of personalized treatment plans for people with HIV, especially when it comes to long-acting medications.
The study suggests that doctors might need to consider BMI more carefully when prescribing LA-CAB/RPV. They could opt for alternative treatments or monitor patients more closely to ensure the medication is working effectively. It's crucial for both patients and healthcare providers to stay informed about these interactions to make the best decisions.
